Terms ending in 2039
Janssen Research & Development, LLC
Every in-force patent on Janssen Research & Development, LLC's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,396,517 | Exo-Aza Spiro Inhibitors of Menin-Mll Interaction In force · High confidence | Janssen Pharmaceutica N.V. | In force | High confidence | |
| US 11,746,161 | Antibodies that Specifically Bind PD-1 and Methods of Use In force · High confidence | Janssen Biotech, Inc. | In force | High confidence | |
| US D1,015,529 | Drug Delivery System In force · High confidence | Janssen Biotech, Inc. | In force | High confidence | |
| US D1,015,531 | Drug Delivery System In force · High confidence | Janssen Biotech, Inc. | In force | High confidence | |
| US 11,780,900 | Glucagon Like Peptide 1 (GLP-1) Fusion Peptide Coupled Cyclic Peptide Tyrosine Tyrosine Conjugates and Uses Thereof In force · High confidence | Janssen Sciences Ireland Unlimited Company | In force | High confidence | |
| US 10,888,550 | Pyrazole Derivatives as MALT1 Inhibitors In force · High confidence | Janssen Pharmaceutica N.V. | In force | High confidence | |
| US D1,032,016 | Single Vial Holder In force · High confidence | Janssen Pharmaceuticals, Inc. | In force | High confidence | |
| US 10,947,252 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION In force · High confidence | Janssen Pharmaceutica N.V. | In force | High confidence | |
| US 11,897,900 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION In force · High confidence | Janssen Pharmaceutica N.V. | In force | High confidence | |
| US 11,707,463 | FGFR2 Inhibitors for the Treatment of Cholangiocarcinoma In force · High confidence | Janssen Pharmaceutica N.V. | In force | High confidence |
10 of 10 patents shown. Soonest term end first, then patent number.
1 of these is in force and held by Janssen Research & Development, LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.